Details of the Drug Combinations

General Information of This Drug (ID: DMCLWDJ)

• Drug Name: Lumacaftor (DMCLWDJ)
• Synonyms: VRT-325; VRT-422; VRT-532; VX-809

Indication

Cystic fibrosis; ICD 11: CA25; Status: Phase 2 [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lumacaftor + Panobinostat	DCNK12C	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ciprofloxacin XR + Lumacaftor	DCI59ZK	Ciprofloxacin XR	Cystic Fibrosis	[3]
Lumacaftor + Itraconazole	DCTURSU	Itraconazole	Cystic Fibrosis	[3]
Lumacaftor + Ivacaftor	DCD6K9J	Ivacaftor	Cystic Fibrosis	[3]
Rifampicin + Lumacaftor	DC3GF8W	Rifampicin	Cystic Fibrosis	[3]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lumacaftor + Ivacaftor	DCEIVC9	Ivacaftor	Cystic fibrosis; Acute lung injury	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7481).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT01768663) A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
• [4] FDA Drug Development and Drug Interactions